- Learn or refresh the differences in pharmacodynamics and pharmacokinetics of currently clinically approved NOACs.
- Learn and interpret real world data on the use of NOACs in patients with AF and concomitant disease. Aspects that may allow a differentiated use of NOACs in these patients.
- Understand the principles of reversal agents in patients with severe bleeding on NOAC therapy. Learn the appropriate clinical use of the first approved NOAC antidote idaracuzimab.
- Learn about the emergency situations which may and which may not require NOAC reversal. Understand the issue of long-term therapy after an acute sever bleeding event in patients on NOAC therapy.